Table 1.
Patients’ demographic and clinical data at baseline in the placebo and omega-3 group
| Characteristics | Placebo (n = 20) | Omega-3 fatty acids (n = 25) | P value |
|---|---|---|---|
| Age (y) (± SD) |
57.2 (±15.19) |
56.8 (±13.09) |
0.925 |
| Sex, n (%) |
|
|
0.592 |
| Females |
8 (40) |
12 (48) |
|
| Males |
12 (60) |
13 (52) |
|
| Hemodialysis duration (mo) (± SD) |
72.05 (±60.51) |
59.88 (±45.69) |
0.450 |
| Dialysis adequacy (Kt/V) |
1.27 ± 0.15 |
1.39 ± 0.22 |
0.057 |
| Cause of end-stage renal disease, n (%) |
|
|
0.624 |
| Diabetes |
7 (35) |
12 (48) |
|
| Hypertension |
8 (40) |
9 (36) |
|
| Other causes | 5 (25) | 4 (16) |
Note: Age and hemodialysis duration are expressed as mean ± SD.